Business Wire

Kymeta Welcomes Industry Leaders to Board of Advisors

14.1.2025 17:00:00 CET | Business Wire | Press release

Share

The world-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com) announced today the addition of two new members to the Board of Advisors, James Geurts and Elizabeth Kimber.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114298718/en/

(Graphic: Business Wire)

The Honorable James Geurts, known to most as Hondo, has over three decades of leadership in the national security sector, including service as the Under Secretary of the Navy, the Department’s second-highest-ranking civilian, responsible for the effective global business operations of the U.S. Navy and Marine Corps team. From 2017 until 2021, after his Presidential Appointment and unanimous Senate confirmation, he served as the Assistant Secretary of the Navy for Research, Development and Acquisition. Since his retirement from government, Geurts has worked extensively to improve the Nation’s defense industrial base and mentors public and private sector teams on scalability, agility, innovation, teamwork, talent development, and leadership.

“Having dedicated much of my career to serving our nation and leading teams in complex, high-stakes environments, I am deeply honored to join Kymeta as a Board Advisor,” stated James Geurts. “Their commitment to innovation, operational excellence, and leadership aligns closely with the principles I have upheld throughout my service. I look forward to contributing my experience and insights to help drive the company's continued growth and success in serving its customers, stakeholders, and communities.”

Elizabeth (Beth) Kimber is a 37-year veteran of the Central Intelligence Agency (CIA) who culminated her career as the Deputy Director of CIA for Operations (DDO) and oversaw CIA’s worldwide HUMINT operations and covert action missions. She also served as Acting Deputy Director of CIA; Assistant Director of CIA for Europe and Eurasia; Deputy Director of the National Clandestine Service, and Chief, Special Operations Department, Counterterrorism Center. She spent 18 years in the field including in assignments as Chief of Station / DNI Representative. In 2022, Kimber joined Two Six Technologies as Vice President of Intelligence Community Strategy. She also serves on the ManTech Board of Directors.

“Having spent a career supporting national security, I am honored to be a part of Kymeta’s Board of Advisors and help showcase their cutting-edge technologies and solutions to national security partners,” said Elizabeth Kimber. “Kymeta has demonstrated a steadfast commitment to innovation, integrity, and driving meaningful impact in its industry. I look forward to leveraging my experience in intelligence, risk management, and organizational leadership to support the company’s mission and help guide its continued growth and success in an ever-evolving world.”

“We are thrilled to welcome Elizabeth and James to our Board of Advisors,” said Rick Bergman, CEO and President, Kymeta. “Their voice and expertise are perfectly suited for helping Kymeta advance our vision of securing the future with innovative technology. Their extensive backgrounds in defense and space sectors are perfectly suited to help guide our business to the next phase of growth.”

About Kymeta

Kymeta revolutionizes satellite communications through Intelligent Communications Platforms (ICPs). Founded in 2012 and headquartered in Redmond, Washington, Kymeta leverages cutting-edge metamaterial-based science to engineer, manufacture and deliver resilient connectivity and enhanced situational awareness for critical, mobile applications. Backed by U.S. and international patents our electronically steered flat panel antennas enable seamless communications on-the-move. With software-defined solutions, hybrid multi-network capabilities, and edge processing, we integrate satellite and cellular networks, ensuring continuous connectivity in challenging environments. Kymeta solutions serve government, military, maritime, transport, and public safety clients worldwide, providing uninterrupted connectivity and spatial intelligence anywhere, anytime. With over 150 patents, Kymeta is shaping the future of global communications, dedicated to delivering reliable, efficient, and intelligent connectivity solutions for an increasingly mobile and connected world.

For more information, visit kymetacorp.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114298718/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye